We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Novel Medications for Opiate Detoxification - 4

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000279
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : June 18, 2020
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University

Tracking Information
First Submitted Date  ICMJE September 20, 1999
First Posted Date  ICMJE September 21, 1999
Last Update Posted Date June 18, 2020
Study Start Date  ICMJE September 1994
Actual Primary Completion Date August 1999   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 23, 2005)		 Withdrawal severity
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Novel Medications for Opiate Detoxification - 4
Official Title  ICMJE Novel Medications for Opiate Detoxification
Brief Summary The purpose of this study is to evaluate novel medications for opiate detoxification.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Primary Purpose: Treatment
Condition  ICMJE
  • Opioid-Related Disorders
  • Substance-Related Disorders
Intervention  ICMJE Drug: Clonidine
Study Arms  ICMJE Not Provided
Publications * AM J Drug & Alc. Abuse 21(4): 453-467, 1995; Neuropsychopharm 13(4): 323-333, 1995; Neuropsychopharm 14(3): 187-193, 1996; J Pharma & Experimental Therapeutics 276(3): 1128-1135, 1996.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: June 23, 2005)		 0
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE August 1999
Actual Primary Completion Date August 1999   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE Please contact site for information.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00000279
Other Study ID Numbers  ICMJE NIDA-09250-4
P50DA009250 ( U.S. NIH Grant/Contract )
P50-09250-4
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Yale University
Original Responsible Party Not Provided
Current Study Sponsor  ICMJE Yale University
Original Study Sponsor  ICMJE National Institute on Drug Abuse (NIDA)
Collaborators  ICMJE
  • National Institute on Drug Abuse (NIDA)
  • VA Connecticut Healthcare System
Investigators  ICMJE
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
PRS Account Yale University
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP